These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18340662)

  • 1. Cetuximab for colorectal cancer.
    Roila F; Garassino MC; Mantica C
    N Engl J Med; 2008 Mar; 358(11):1196; author reply 1196-7. PubMed ID: 18340662
    [No Abstract]   [Full Text] [Related]  

  • 2. Cetuximab for colorectal cancer.
    Yang F; Fu D; Ni Q
    N Engl J Med; 2008 Mar; 358(11):1195; author reply 1196-7. PubMed ID: 18337611
    [No Abstract]   [Full Text] [Related]  

  • 3. Cetuximab for colorectal cancer.
    van der Spek E; Sonke GS
    N Engl J Med; 2008 Mar; 358(11):1196; author reply 1196-7. PubMed ID: 18340661
    [No Abstract]   [Full Text] [Related]  

  • 4. Cetuximab for colorectal cancer.
    Fraggetta F; Pelosi G
    N Engl J Med; 2008 Mar; 358(11):1196; author reply 1196-7. PubMed ID: 18340663
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
    Burtness B
    Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting EGFR in colorectal cancer.
    Messersmith WA; Ahnen DJ
    N Engl J Med; 2008 Oct; 359(17):1834-6. PubMed ID: 18946069
    [No Abstract]   [Full Text] [Related]  

  • 7. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab.
    Graham J; Muhsin M; Kirkpatrick P
    Nat Rev Drug Discov; 2004 Jul; 3(7):549-50. PubMed ID: 15272498
    [No Abstract]   [Full Text] [Related]  

  • 9. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.
    Kim R; Kubal T
    Clin Colorectal Cancer; 2012 Jun; 11(2):85-7. PubMed ID: 22169039
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
    You B; Chen EX
    J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panitumumab (Vectibix) for metastatic colorectal cancer.
    Med Lett Drugs Ther; 2007 Apr; 49(1259):35-6. PubMed ID: 17450113
    [No Abstract]   [Full Text] [Related]  

  • 12. Introduction: Emerging therapies with epidermal growth factor receptor-targeted agents in colorectal cancer.
    Chu E
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S60-1. PubMed ID: 16336750
    [No Abstract]   [Full Text] [Related]  

  • 13. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
    Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
    Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab vs EGFR antibodies in metastatic colorectal cancer.
    Venook AP
    Clin Adv Hematol Oncol; 2015 Feb; 13(2):90-2. PubMed ID: 25774477
    [No Abstract]   [Full Text] [Related]  

  • 15. Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy?
    Younes M
    J Clin Oncol; 2005 Feb; 23(4):923; author reply 923-4. PubMed ID: 15681544
    [No Abstract]   [Full Text] [Related]  

  • 16. Cetuximab for the treatment of colorectal cancer.
    Jonker DJ; O'Callaghan CJ; Karapetis CS; Zalcberg JR; Tu D; Au HJ; Berry SR; Krahn M; Price T; Simes RJ; Tebbutt NC; van Hazel G; Wierzbicki R; Langer C; Moore MJ
    N Engl J Med; 2007 Nov; 357(20):2040-8. PubMed ID: 18003960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
    N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab: from biology to the care of colorectal cancer patients.
    Vincenzi B; Santini D; Tonini G
    Future Oncol; 2007 Oct; 3(5):497-9. PubMed ID: 17927513
    [No Abstract]   [Full Text] [Related]  

  • 19. [Long-term beneficial effects of cetuximab in a woman with metastasised rectal carcinoma without expression of the epidermal growth factor receptor].
    Kroep JR; Gelderblom H; Collen AF; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Nov; 150(46):2555-9. PubMed ID: 17152334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
    Piront P; Van Daele D; Belaiche J; Polus M
    Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.